<li>aceclofenac<p>aceclofenac, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>acemetacin<p>acemetacin, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>albiglutide<p>prednisone decreases effects of albiglutide by pharmacodynamic antagonism. Use Caution/Monitor. Corticosteroids may diminish hypoglycemic effect of antidiabetic agents. Monitor blood glucose levels carefully. .</p></li><li>alitretinoin<p>prednisone will decrease the level or effect of alitretinoin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>almotriptan<p>prednisone will decrease the level or effect of almotriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>alprazolam<p>prednisone will decrease the level or effect of alprazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>amiodarone<p>prednisone will decrease the level or effect of amiodarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>amiodarone will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>amobarbital<p>amobarbital will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>antithrombin alfa<p>prednisone, antithrombin alfa. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>antithrombin iii<p>prednisone, antithrombin iii. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>aprepitant<p>aprepitant will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>prednisone will decrease the level or effect of aprepitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>argatroban<p>prednisone, argatroban. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>aripiprazole<p>prednisone will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>armodafinil<p>armodafinil will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>artemether/lumefantrine<p>artemether/lumefantrine will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>prednisone will decrease the level or effect of artemether/lumefantrine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>asparaginase<p>prednisone increases toxicity of asparaginase by pharmacodynamic synergism. Use Caution/Monitor.  Asparaginase transiently inhibits insulin production contributing to hyperglycemia seen during concurrent corticosteroid therapy. .</p></li><li>aspirin<p>aspirin, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>aspirin rectal<p>aspirin rectal, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>aspirin/citric acid/sodium bicarbonate, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>atazanavir<p>atazanavir will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>atorvastatin<p>prednisone will decrease the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>atorvastatin will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>atracurium<p>atracurium, prednisone. Other (see comment). Use Caution/Monitor. 
Comment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy.</p></li><li>axitinib<p>prednisone decreases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>bazedoxifene/conjugated estrogens<p>prednisone will decrease the level or effect of bazedoxifene/conjugated estrogens by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>belatacept<p>belatacept and prednisone both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor.</p></li><li>bemiparin<p>prednisone, bemiparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>bivalirudin<p>prednisone, bivalirudin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>bosentan<p>bosentan will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>budesonide<p>budesonide will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>buspirone<p>prednisone will decrease the level or effect of buspirone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>butabarbital<p>butabarbital will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>butalbital<p>butalbital will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>carbamazepine<p>prednisone will decrease the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>celecoxib<p>celecoxib, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>cholera vaccine<p>prednisone decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine.</p></li><li>cholestyramine<p>cholestyramine decreases levels of prednisone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>choline magnesium trisalicylate<p>choline magnesium trisalicylate, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>cilostazol<p>prednisone will decrease the level or effect of cilostazol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>cinacalcet<p>prednisone will decrease the level or effect of cinacalcet by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ciprofloxacin<p>prednisone and ciprofloxacin both increase  Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.</p></li><li>cisatracurium<p>cisatracurium, prednisone. Other (see comment). Use Caution/Monitor. 
Comment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy.</p></li><li>clarithromycin<p>clarithromycin will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>clarithromycin increases levels of prednisone by decreasing metabolism. Use Caution/Monitor. Risk of toxic steroid concentrations and altered mental status.</p></li><li>clobetasone<p>clobetasone will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>clopidogrel<p>prednisone will increase the level or effect of clopidogrel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. CYP3A4 inducers may increase the metabolism of clopidogrel to its active metabolite. Monitor patients for potential increase in antiplatelet effects when CYP3A4 inducers are used in combination with clopidogrel</p></li><li>clotrimazole<p>clotrimazole will decrease the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>clozapine<p>prednisone will decrease the level or effect of clozapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>colchicine<p>prednisone will decrease the level or effect of colchicine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>conivaptan<p>conivaptan will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>prednisone will decrease the level or effect of conivaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>conjugated estrogens<p>prednisone will decrease the level or effect of conjugated estrogens by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>conjugated estrogens, vaginal<p>prednisone will decrease the level or effect of conjugated estrogens, vaginal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>cortisone<p>cortisone will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>cyclosporine<p>cyclosporine will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>daclatasvir<p>daclatasvir will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>dalteparin<p>prednisone, dalteparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>darifenacin<p>darifenacin will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>darunavir<p>darunavir will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>prednisone will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>dasatinib<p>dasatinib will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>deferasirox<p>deferasirox will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>delavirdine<p>delavirdine will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>denosumab<p>prednisone, denosumab. Other (see comment). Use Caution/Monitor. 
Comment: Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections.</p></li><li>dexamethasone<p>dexamethasone will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>dhea, herbal<p>dhea, herbal will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>diazepam<p>prednisone will decrease the level or effect of diazepam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>dichlorphenamide<p>dichlorphenamide and prednisone both decrease  serum potassium. Use Caution/Monitor.</p></li><li>diclofenac<p>diclofenac, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>dienogest/estradiol valerate<p>prednisone will decrease the level or effect of dienogest/estradiol valerate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Advise women to use alternative method of contraception or back-up method when moderate or weak enzyme inducer is used with combination contraceptives. Back-up contraception should be continued for 28 days after discontinuing  medication to ensure contraceptive reliability. </p></li><li>diflunisal<p>diflunisal, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>diltiazem<p>diltiazem will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>diltiazem will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>dronedarone<p>dronedarone will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>dronedarone will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>dyphylline<p>prednisone will decrease the level or effect of dyphylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>efavirenz<p>efavirenz will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>eletriptan<p>prednisone will decrease the level or effect of eletriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>eliglustat<p>eliglustat increases levels of prednisone by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the P-gp substrate and titrate to clinical effect.</p></li><li>enoxaparin<p>prednisone, enoxaparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>erythromycin base<p>erythromycin base will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>erythromycin ethylsuccinate<p>erythromycin ethylsuccinate will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>erythromycin lactobionate<p>erythromycin lactobionate will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>erythromycin stearate<p>erythromycin stearate will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>eslicarbazepine acetate<p>eslicarbazepine acetate will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>estradiol<p>prednisone will decrease the level or effect of estradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>estrogens conjugated synthetic<p>prednisone will decrease the level or effect of estrogens conjugated synthetic by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>estropipate<p>prednisone will decrease the level or effect of estropipate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ethotoin<p>ethotoin will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>ethotoin will decrease the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>etodolac<p>etodolac, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>etoricoxib<p>etoricoxib, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>etravirine<p>prednisone will decrease the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>etravirine will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>eucalyptus<p>eucalyptus will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>exenatide injectable solution<p>prednisone decreases effects of exenatide injectable solution by pharmacodynamic antagonism. Use Caution/Monitor. Corticosteroids may diminish hypoglycemic effect of antidiabetic agents. Monitor blood glucose levels carefully. .</p></li><li>exenatide injectable suspension<p>prednisone decreases effects of exenatide injectable suspension by pharmacodynamic antagonism. Use Caution/Monitor. Corticosteroids may diminish hypoglycemic effect of antidiabetic agents. Monitor blood glucose levels carefully.</p></li><li>felodipine<p>prednisone will decrease the level or effect of felodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>felodipine will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>fenbufen<p>fenbufen, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>fenoprofen<p>fenoprofen, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>fesoterodine<p>prednisone will decrease the level or effect of fesoterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>fingolimod<p>prednisone increases effects of fingolimod by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Concomitant therapy is expected to increase the risk of immunosuppression. Use caution when switching patients from long-acting therapies with immune effects. .</p></li><li>fluconazole<p>fluconazole will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>fludrocortisone<p>fludrocortisone will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>flurbiprofen<p>flurbiprofen, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>fondaparinux<p>prednisone, fondaparinux. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>fosamprenavir<p>fosamprenavir will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>prednisone will decrease the level or effect of fosamprenavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>fosphenytoin<p>fosphenytoin will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>fosphenytoin will decrease the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>gemifloxacin<p>prednisone and gemifloxacin both increase  Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.</p></li><li>glycerol phenylbutyrate<p>prednisone decreases effects of glycerol phenylbutyrate by Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels; monitor ammonia levels closely when glycerol phenylbutyrate is coadministered with corticosteroids.</p></li><li>grapefruit<p>grapefruit will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>griseofulvin<p>griseofulvin will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>hemin<p>prednisone decreases effects of hemin by pharmacodynamic synergism. Use Caution/Monitor. Drugs that increase delta-aminolevulinic acid synthetase may decrease hemin effect.</p></li><li>heparin<p>prednisone, heparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>hexobarbital<p>hexobarbital will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>hydrocortisone<p>hydrocortisone will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>hydroxyprogesterone caproate<p>prednisone will decrease the level or effect of hydroxyprogesterone caproate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ibuprofen<p>ibuprofen, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>iloperidone<p>prednisone will decrease the level or effect of iloperidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>indacaterol, inhaled<p>prednisone, indacaterol, inhaled. serum potassium. Use Caution/Monitor. Combination may increase risk of hypokalemia.</p></li><li>indinavir<p>indinavir will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>indinavir will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>indomethacin<p>indomethacin, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>influenza virus vaccine (h5n1)<p>prednisone decreases effects of influenza virus vaccine (h5n1) by pharmacodynamic antagonism. Use Caution/Monitor. Corticosteroids used in greater than physiologic doses may reduce immune response to H5N1 vaccine.</p></li><li>influenza virus vaccine (h5n1), adjuvanted<p>prednisone decreases effects of influenza virus vaccine (h5n1), adjuvanted by pharmacodynamic antagonism. Use Caution/Monitor. Corticosteroids used in greater than physiologic doses may reduce immune response to H5N1 vaccine.</p></li><li>influenza virus vaccine quadrivalent, recombinant<p>prednisone decreases effects of influenza virus vaccine quadrivalent, recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immune response to vaccine may be decreased in immunocompromised individuals.</p></li><li>influenza virus vaccine trivalent, recombinant<p>prednisone decreases effects of influenza virus vaccine trivalent, recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immune response to vaccine may be decreased in immunocompromised individuals.</p></li><li>insulin degludec<p>prednisone decreases effects of insulin degludec by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Endogneous cortisol is a regulatory hormone that increases blood glucose levels; exogenous systemic corticosteroids have been associated with hyperglycemia and may cause diabetes with chronic, high dose use; dose of antidiabetic agents may need adjustment and increased frequency of glucose monitoring may be required.</p></li><li>insulin degludec/insulin aspart<p>prednisone decreases effects of insulin degludec/insulin aspart by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Endogneous cortisol is a regulatory hormone that increases blood glucose levels; exogenous systemic corticosteroids have been associated with hyperglycemia and may cause diabetes with chronic, high dose use; dose of antidiabetic agents may need adjustment and increased frequency of glucose monitoring may be required.</p></li><li>insulin inhaled<p>prednisone decreases effects of insulin inhaled by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Endogneous cortisol is a regulatory hormone that increases blood glucose levels; exogenous systemic corticosteroids have been associated with hyperglycemia and may cause diabetes with chronic, high dose use; dose of antidiabetic agents may need adjustment and increased frequency of glucose monitoring may be required.</p></li><li>isoniazid<p>isoniazid will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>itraconazole<p>itraconazole will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ixabepilone<p>prednisone will decrease the level or effect of ixabepilone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ketoconazole<p>ketoconazole will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ketoprofen<p>ketoprofen, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>ketorolac<p>ketorolac, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>ketorolac intranasal<p>ketorolac intranasal, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>lacidipine<p>prednisone will decrease the level or effect of lacidipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>lapatinib<p>lapatinib will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>lapatinib will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>lepirudin<p>prednisone, lepirudin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>lercanidipine<p>prednisone will decrease the level or effect of lercanidipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>levobupivacaine<p>prednisone will decrease the level or effect of levobupivacaine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>levofloxacin<p>prednisone and levofloxacin both increase  Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.</p></li><li>linagliptin<p>prednisone will increase the level or effect of linagliptin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Use of alternative treatments is strongly recommended when linagliptin is to be administered with a CYP3A4 inducer</p></li><li>liraglutide<p>prednisone decreases effects of liraglutide by pharmacodynamic antagonism. Use Caution/Monitor. Corticosteroids may diminish hypoglycemic effect of antidiabetic agents. Monitor blood glucose levels carefully. .</p></li><li>lopinavir<p>prednisone will decrease the level or effect of lopinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>loratadine<p>prednisone will decrease the level or effect of loratadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>loratadine will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>lornoxicam<p>lornoxicam, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>lumacaftor/ivacaftor<p>lumacaftor/ivacaftor decreases levels of prednisone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. A higher dose of corticosteroids may be required for desired clinical effect.</p></li><li>lumefantrine<p>prednisone will decrease the level or effect of lumefantrine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>lumefantrine will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>maraviroc<p>prednisone will decrease the level or effect of maraviroc by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>marijuana<p>marijuana will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>meclofenamate<p>meclofenamate, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>mefenamic acid<p>mefenamic acid, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>meloxicam<p>meloxicam, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>meningococcal group b vaccine<p>prednisone decreases effects of meningococcal group b vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Individuals with altered immunocompetence may have reduced immune responses to the vaccine.</p></li><li>mephobarbital<p>mephobarbital will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>mestranol<p>prednisone will decrease the level or effect of mestranol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>methadone<p>prednisone will decrease the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>methylprednisolone<p>methylprednisolone will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>metronidazole<p>metronidazole will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>mibefradil<p>mibefradil will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>miconazole vaginal<p>miconazole vaginal will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>midazolam<p>prednisone will decrease the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>midazolam will decrease the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>modafinil<p>modafinil will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>moxifloxacin<p>prednisone and moxifloxacin both increase  Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.</p></li><li>nabumetone<p>nabumetone, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>naproxen<p>naproxen, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>nefazodone<p>nefazodone will decrease the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>nelfinavir<p>nelfinavir will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>nevirapine<p>nevirapine will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>nicardipine<p>prednisone will decrease the level or effect of nicardipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>nicardipine will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>nifedipine<p>nifedipine will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>nifedipine will decrease the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>nilotinib<p>nilotinib will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>nilotinib will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>nisoldipine<p>prednisone will decrease the level or effect of nisoldipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>norfloxacin<p>prednisone and norfloxacin both increase  Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.</p></li><li>ocrelizumab<p>prednisone and ocrelizumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Coadministration of ocrelizumab with high doses of corticosteroids is expected to increase the risk of immunosuppression.</p></li><li>ofloxacin<p>prednisone and ofloxacin both increase  Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.</p></li><li>olodaterol inhaled<p>prednisone and olodaterol inhaled both decrease  serum potassium. Use Caution/Monitor.</p></li><li>ombitasvir/paritaprevir/ritonavir<p>ombitasvir/paritaprevir/ritonavir will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Paritaprevir and ritonavir inhibit P-gp. Caution if coadministered with P-gp substrates.</p></li><li>oxaprozin<p>oxaprozin, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>oxcarbazepine<p>oxcarbazepine will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>oxiconazole<p>oxiconazole will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>pancuronium<p>pancuronium, prednisone. Other (see comment). Use Caution/Monitor. 
Comment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy.</p></li><li>parecoxib<p>parecoxib, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>pentobarbital<p>pentobarbital will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>phenindione<p>prednisone, phenindione. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>phenobarbital<p>phenobarbital will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>phenobarbital will decrease the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>phenytoin<p>phenytoin will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>phenytoin will decrease the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>piroxicam<p>piroxicam, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>ponatinib<p>ponatinib increases levels of prednisone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>posaconazole<p>posaconazole will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>prednisolone<p>prednisolone will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>primidone<p>primidone will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>protamine<p>prednisone, protamine. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>quercetin<p>quercetin will decrease the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>quetiapine<p>prednisone will decrease the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>quinidine<p>prednisone will decrease the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>quinupristin/dalfopristin<p>quinupristin/dalfopristin will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ranolazine<p>ranolazine will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>repaglinide<p>prednisone will decrease the level or effect of repaglinide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>reserpine<p>reserpine will decrease the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>rifampin<p>rifampin will decrease the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>rifapentine<p>rifapentine will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>rimonabant<p>prednisone will decrease the level or effect of rimonabant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ritonavir<p>ritonavir will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>prednisone will decrease the level or effect of ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>ritonavir will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>rocuronium<p>rocuronium, prednisone. Other (see comment). Use Caution/Monitor. 
Comment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy.</p></li><li>rufinamide<p>rufinamide will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>salicylates (non-asa)<p>salicylates (non-asa), prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>salsalate<p>salsalate, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>saquinavir<p>prednisone will decrease the level or effect of saquinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>secobarbital<p>secobarbital will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>simvastatin<p>simvastatin will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>sipuleucel-t<p>prednisone decreases effects of sipuleucel-t by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.</p></li><li>sirolimus<p>sirolimus will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>sitaxentan<p>sitaxentan will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>sodium picosulfate/magnesium oxide/anhydrous citric acid<p>prednisone, sodium picosulfate/magnesium oxide/anhydrous citric acid.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May be associated with fluid and electrolyte imbalances such as hypokalemia.</p></li><li>sodium sulfate/potassium sulfate/magnesium sulfate<p>prednisone and sodium sulfate/potassium sulfate/magnesium sulfate both decrease  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol<p>prednisone and sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol both decrease  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>solifenacin<p>prednisone will decrease the level or effect of solifenacin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>somatrem<p>prednisone decreases effects of somatrem by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>sorafenib<p>prednisone decreases levels of sorafenib by increasing metabolism. Use Caution/Monitor.</p></li><li>spironolactone<p>spironolactone will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>st john's wort<p>st john's wort will decrease the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>succinylcholine<p>succinylcholine, prednisone. Other (see comment). Use Caution/Monitor. 
Comment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy.</p></li><li>sulfasalazine<p>sulfasalazine, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>sulindac<p>sulindac, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>tacrolimus<p>prednisone will decrease the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>tacrolimus will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>telaprevir<p>telaprevir increases levels of prednisone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Co-administration of systemic corticosteroids and telaprevir is not recommended. Systemic corticosteroids such as prednisone are CYP3A4 substrates. Since telaprevir is a potent CYP3A4 inhibitor, plasma concentrations of these corticosteroids can be increased significantly. .</p></li><li>telithromycin<p>telithromycin will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>theophylline<p>prednisone will decrease the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>tinzaparin<p>prednisone, tinzaparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>tipranavir<p>prednisone will decrease the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>tolfenamic acid<p>tolfenamic acid, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>tolmetin<p>tolmetin, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>tolterodine<p>prednisone will decrease the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>tolvaptan<p>tolvaptan will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>topiramate<p>topiramate will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>trazodone<p>prednisone will decrease the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>trazodone will decrease the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>triamcinolone<p>prednisone will decrease the level or effect of triamcinolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>triazolam<p>prednisone will decrease the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>troglitazone<p>troglitazone will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>troleandomycin<p>troleandomycin will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>vardenafil<p>prednisone will decrease the level or effect of vardenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>vecuronium<p>vecuronium, prednisone. Other (see comment). Use Caution/Monitor. 
Comment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy.</p></li><li>verapamil<p>verapamil will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>prednisone will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>voriconazole<p>voriconazole will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>warfarin<p>prednisone will decrease the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>prednisone, warfarin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>xipamide<p>xipamide, prednisone. pharmacodynamic synergism. Use Caution/Monitor. Risk of hypokalemia.</p></li><li>zafirlukast<p>zafirlukast will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li>